Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from ItalyL. Pasulo, Giuliana Cologni, M. Gambato et al.|Digestive and Liver Disease|2019Cited by 1
THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from ItalyL. Pasulo, Antonio Albanese, Colombatto Piero et al.|Journal of Hepatology|2019Cited by 1
THU-141-Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patientsMartina Gambato, Marie Graciella Pigozzi, Angiola Spinetti et al.|Journal of Hepatology|2019Cited by 1
SAT-262-Long-term liver function outcome and related risk factors in HCV cirrhotic patients treated with direct-acting antiviral therapy: Results from the Navigatore platform in Veneto-ItalyFrancesco Paolo Russo, A. Albertí, Martina Gambato et al.|Journal of Hepatology|2019Cited by 0